The estimated Net Worth of Alec Machiels is at least $14.4 Million dollars as of 17 November 2023. Mr. Machiels owns over 1,250 units of Apellis Pharmaceuticals Inc stock worth over $14,142,181 and over the last 5 years he sold APLS stock worth over $0. In addition, he makes $245,285 as Independent Director at Apellis Pharmaceuticals Inc.
Alec has made over 45 trades of the Apellis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,250 units of APLS stock worth $3,338 on 17 November 2023.
The largest trade he's ever made was exercising 50,000 units of Apellis Pharmaceuticals Inc stock on 20 July 2023 worth over $133,500. On average, Alec trades about 3,606 units every 27 days since 2019. As of 17 November 2023 he still owns at least 368,670 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mr. Machiels stock trades at the bottom of the page.
Alec Machiels, J.D., is Independent Director of the Company. He currently serves as the Founding Managing Partner of CoLift, LLC, which he founded in September 2019. From May 2006 until June 2019, Mr. Machiels served as a Partner at Pegasus Capital Advisors, L.P., a private equity firm that he joined in 2002. Mr. Machiels co-founded Potentia and served as its Chief Executive Officer from 2001 to 2002. Mr. Machiels previously served on the board of directors of several private companies, including Revon, which he cofounded. He started his career as a financial analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman, Sachs & Co. in New York from July 1996 until June 1999. Mr. Machiels received an M.B.A. from Harvard Business School in 2001. Mr. Machiels also received a license in law from KU Leuven Law School in Belgium and a masters in international economics from Konstanz University in Germany.
As the Independent Director of Apellis Pharmaceuticals Inc, the total compensation of Alec Machiels at Apellis Pharmaceuticals Inc is $245,285. There are 12 executives at Apellis Pharmaceuticals Inc getting paid more, with Cedric Francois having the highest compensation of $4,267,180.
Alec Machiels is 47, he's been the Independent Director of Apellis Pharmaceuticals Inc since 2009. There are 16 older and 4 younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
Alec's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: